2025
PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact.
Issa N, Obagi S, Damiani G, Wang J, Bunick C. PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact. Journal Of Drugs In Dermatology 2025, 24: 631-633. PMID: 40465498, DOI: 10.36849/jdd.9089.Peer-Reviewed Original ResearchConceptsPhosphodiesterase-4 inhibitorPhosphodiesterase-4Cyclic adenosine monophosphateClinical impactContraindications to systemic therapyEffective suppression of inflammationInhibition of phosphodiesterase-4Minimal systemic side effectsChronic inflammatory skin diseaseSystemic side effectsInflammatory skin diseaseTherapeutic decision-makingSuppression of inflammationMessenger cyclic adenosine monophosphateClinically meaningful guidanceCombination regimensSystemic therapyRefractory casesTreatment landscapeTargeted therapyLichen planusSkin erythemaAtopic dermatitisSeborrheic dermatitisSide effects
2024
Enhanced Intratumoral Delivery of Immunomodulator Monophosphoryl Lipid A through Hyperbranched Polyglycerol–Coated Biodegradable Nanoparticles
Chang J, Shin K, Lewis J, Suh H, Lee J, Damsky W, Xu S, Bosenberg M, Saltzman W, Girardi M. Enhanced Intratumoral Delivery of Immunomodulator Monophosphoryl Lipid A through Hyperbranched Polyglycerol–Coated Biodegradable Nanoparticles. Journal Of Investigative Dermatology 2024, 145: 593-604. PMID: 39122142, DOI: 10.1016/j.jid.2024.07.019.Peer-Reviewed Original ResearchMonophosphoryl lipid ATumor microenvironmentImmunomodulatory agentsStimulation of anti-tumor immune responseEfficacy of monophosphoryl lipid AT-helper (Th)1 responsesAnti-tumor immune responseTumor-draining lymph nodesToxicity associated with systemic administrationImmune responseModel of malignant melanomaAgonist monophosphoryl lipid ABiodegradable nanoparticlesImmunogenic tumor microenvironmentAntitumor immune responseDraining Lymph NodesSystemic side effectsNatural killer cellsGradual drug releaseKiller cellsAntitumor efficacyMalignant melanomaImproved survivalLymph nodesChemotherapeutic agentsImmune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchConceptsRegulatory myeloid cellsSolid organ transplantationVascularized Composite AllotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejectionIntrathecal Injection of Newborn Mouse for Genome Editing and Drug Delivery.
Lu X, Jiang Y. Intrathecal Injection of Newborn Mouse for Genome Editing and Drug Delivery. Journal Of Visualized Experiments 2024 PMID: 38526075, DOI: 10.3791/65761.Peer-Reviewed Original ResearchConceptsIntrathecal injectionNewborn miceNeonatal pupsInjection of newborn miceReducing systemic side effectsSystemic side effectsPostnatal day 1Local drug concentrationCentral nervous systemDelivery of drugsPotential therapeutic interventionsNeonatal micePreclinical studiesDay 1Newborn pupsSide effectsCerebrospinal fluidDrug concentrationsAdult clinicIntramuscular injectionNervous systemTherapeutic interventionsClinical settingNon-human primatesAccurate delivery
2023
Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation
Kauke-Navarro M, Noel O, Knoedler L, Knoedler S, Panayi A, Stoegner V, Huelsboemer L, Pomahac B. Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation. Journal Of Surgical Research 2023, 291: 176-186. PMID: 37429217, DOI: 10.1016/j.jss.2023.04.028.Peer-Reviewed Original ResearchConceptsImmunosuppressive regimensAllograft rejectionComposite allotransplantationDonor-derived immune cellsDonor-derived T lymphocytesRecipient-derived T cellsPotent immunosuppressive regimensToxic immunosuppressive regimensSolid organ transplantationAntigen-presenting cellsSystemic side effectsVascularized Composite AllotransplantationCD40 knockoutChronic rejectionRejection episodesSystemic immunosuppressionMost patientsImmunomodulatory strategiesTolerance inductionImmune cellsOrgan transplantationT cellsT lymphocytesSide effectsClinical success
2021
A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models
Kauke M, Safi AF, Panayi AC, Palmer WJ, Haug V, Kollar B, Nelms L, Tchiloemba B, Pomahac B. A systematic review of immunomodulatory strategies used in skin-containing preclinical vascularized composite allotransplant models. Journal Of Plastic Reconstructive & Aesthetic Surgery 2021, 75: 586-604. PMID: 34895853, DOI: 10.1016/j.bjps.2021.11.003.Peer-Reviewed Original ResearchConceptsSystematic reviewImmunomodulatory strategiesPreclinical researchAvailable immunosuppressive regimensCurrent standard regimenSystemic side effectsDrug-based approachesMeta-Analyses (PRISMA) guidelinesVCA modelPreferred Reporting ItemsHind limb modelNovel immunomodulatoryRejection episodesAcute rejectionImmunosuppressive regimensStandard regimenAllograft acceptanceAlloimmune responseSuppression therapyImmunomodulation strategiesLimb transplantsPreclinical modelsRat modelHuman trialsTherapeutic approaches766 Toward safe, systemic delivery of synthetic TLR7/8 agonists using Bottlebrush Prodrugs (BPDs)
Bhagchandani S, Milling L, Liu B, Fessenden T, Spranger S, Johnson J, Irvine D. 766 Toward safe, systemic delivery of synthetic TLR7/8 agonists using Bottlebrush Prodrugs (BPDs). Journal For ImmunoTherapy Of Cancer 2021, 9: a801-a801. DOI: 10.1136/jitc-2021-sitc2021.766.Peer-Reviewed Original ResearchTLR reporter cellsSystemic deliveryAnti-PD-1 antibody treatmentMC38 colon cancer modelImidazoquinoline derivativesToll-like receptor agonistsSerum cytokine levelsMaximum tolerable doseSystemic side effectsImproved survival ratesReporter cellsAnti-tumor efficacyColon cancer modelCytokine levelsMetastatic diseaseTLR agonistsTLR7/8 agonistAntibody treatmentTLR activationTreatment of cancerTolerable doseReceptor agonistIntravenous administrationTopical solutionSide effects
2020
Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides.
Hu JK, Carlson K, Girardi M. Low-Dose Intralesional Recombinant Interferon-α2b in the Treatment of Mycosis Fungoides. The Yale Journal Of Biology And Medicine 2020, 93: 41-44. PMID: 32226334, PMCID: PMC7087069.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesLocal immunotherapyIntralesional injectionSide effectsAssociated systemic side effectsSkin-homing T cellsEarly-stage mycosis fungoidesTreatment of MFCases of MFGeneralized side effectsStage mycosis fungoidesT-cell lymphomaSystemic side effectsRecombinant interferon α2bImprovement of diseaseSystemic therapyRecalcitrant lesionsMF patientsTherapeutic optionsMalignant CD4Intramuscular injectionMF lesionsSystemic administrationSubsequent dosingRe-appraising the potential of naringin for natural, novel orthopedic biotherapies
Yu KE, Alder KD, Morris MT, Munger AM, Lee I, Cahill SV, Kwon HK, Back J, Lee FY. Re-appraising the potential of naringin for natural, novel orthopedic biotherapies. Therapeutic Advances In Musculoskeletal Disease 2020, 12: 1759720x20966135. PMID: 33343723, PMCID: PMC7727086, DOI: 10.1177/1759720x20966135.Peer-Reviewed Original ResearchBone morphogenetic proteinExtracellular signal-related kinase (ERK) pathwayRANK/RANKL interactionNumerous molecular pathwaysWnt/β-cateninBone resident cellsStem cell precursorsCellular differentiationKinase pathwayMorphogenetic proteinsPotential of naringinMolecular pathwaysΒ-cateninCellular mechanismsBone-preserving effectCommon musculoskeletal pathologiesEstrogen-sensitive tissuesOsteolytic bone diseaseCommon musculoskeletal conditionsMusculoskeletal developmentSystemic side effectsTreatment of osteoporosisDegenerative joint diseaseCell precursorsBone microenvironment
2019
Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders
Barahona MJ, Baratta V, Ollodart J, Mulligan D, Geibel JP. Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders. Future Medicinal Chemistry 2019, 11: 847-855. PMID: 30994367, PMCID: PMC8008207, DOI: 10.4155/fmc-2018-0313.Peer-Reviewed Original ResearchConceptsSignificant worldwide disease burdenSpectrum of illnessWorldwide disease burdenIntestinal fluid secretionSystemic side effectsCalcium-sensing receptorNovel therapeutic targetG protein-coupled receptorsSurgical therapyPharmaceutical optionsMucosal integrityDisease burdenIntestinal disordersNutraceutical therapyGastrointestinal diseasesGastrointestinal illnessSide effectsTherapeutic targetFluid secretionIntestinal cellsTherapyAdverse effectsNovel nutraceuticalsCaSRIllnessBisphosphonate-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Tumor of Bone
Greenberg DD, Lee FY. Bisphosphonate-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Tumor of Bone. American Journal Of Clinical Oncology 2019, 42: 231-237. PMID: 30811352, DOI: 10.1097/coc.0000000000000504.Peer-Reviewed Original ResearchConceptsGiant cell tumorAdjuvant therapyLocal adjuvant therapySystemic side effectsAvascular necrosisCell tumorsSide effectsMusculoskeletal Tumor Society scoreOsteoclast-like giant cellsAggressive bone resorptionTherapeutic Level IVHigh-speed burringLocal recurrence rateAtypical femur fracturesLevel of evidenceTraditional adjuvant therapyBone cementAtypical fracturesSystemic bisphosphonatesPulmonary metastasesSociety ScoreCurettage proceduresRecurrence rateFemur fracturesPolymethylmethacrylate bone cement
2016
Ocular Manifestations of Inherited Phospholipase-C&ggr;2–Associated Antibody Deficiency and Immune Dysregulation
Di Zazzo A, Tahvildari M, Florakis G, Dana R. Ocular Manifestations of Inherited Phospholipase-C&ggr;2–Associated Antibody Deficiency and Immune Dysregulation. Cornea 2016, 35: 1656-1657. PMID: 27442322, PMCID: PMC5250612, DOI: 10.1097/ico.0000000000000951.Peer-Reviewed Original ResearchConceptsOcular manifestationsOcular surfaceAntibody deficiencyImmune dysregulationEpisodes of ocular inflammationInterleukin-1Anti-IL-1 therapySystemic immunomodulatory treatmentSystemic side effectsBouts of inflammationInterstitial lung diseaseRecurrent inflammatory diseaseInterleukin-1 productionCorneal pannusCorneal involvementCorneal scarringOcular inflammationOral prednisoneOcular symptomsSystemic immunosuppressionImmunomodulatory treatmentSystemic manifestationsLung diseaseActive lesionsPartial improvement
2013
Contraception
Belkind U, Coupey S, Godfrey E, Kottke M, Patterson‐Rose S, Braverman P, Yen S, Isley M, Kaunitz A, Duffy K, Gold M. Contraception. 2013, 205-233. DOI: 10.1002/9781118538555.ch34.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsIntrauterine deviceContraceptive methodsSide effectsMechanism of actionUpper female genital tractYoung womenHormonal oral contraceptionPelvic inflammatory diseaseCommon side effectsOral contraceptive pillsLevonorgestrel intrauterine deviceBarrier contraceptive methodsRapid repeat pregnancyFirst-line contraceptionSystemic side effectsFemale genital tractPopular birth control methodBirth controlBirth control methodsContraceptive regimenLea's ShieldMethod initiationMenstrual abnormalitiesNext menstruationOral contraception
2011
IFN-γ Acts on the Airway Epithelium To Inhibit Local and Systemic Pathology in Allergic Airway Disease
Mitchell C, Provost K, Niu N, Homer R, Cohn L. IFN-γ Acts on the Airway Epithelium To Inhibit Local and Systemic Pathology in Allergic Airway Disease. The Journal Of Immunology 2011, 187: 3815-3820. PMID: 21873527, PMCID: PMC3178669, DOI: 10.4049/jimmunol.1100436.Peer-Reviewed Original ResearchConceptsAirway epitheliumAllergic airway inflammationAllergic airway diseaseTh2 cell activationGoal of therapyProduction of IFNAdministration of medicationsSystemic side effectsAirway mucosal surfaceAirway epithelial cellsSites of inflammationIFN-γ actionAirway inflammationAirway obstructionPersistent asthmaRefractory asthmaAirway diseaseIFN-γRTh1 cellsPathological responseSystemic pathologyEffector functionsSide effectsBone marrowAsthma
2009
Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907).
Kornblith A, Archer L, Lan L, Kimmick G, Partridge A, Casey R, Bennett S, Hudis C, Winer E, Cohen H, Muss H. Quality of Life of Early Stage Breast Cancer Patients 65 Years Old or Older Randomized to Standard Chemotherapy or Capecitabine: A Cancer and Leukemia Group B Study (CALGB 49907). Cancer Research 2009, 69: 5035-5035. DOI: 10.1158/0008-5472.sabcs-09-5035.Peer-Reviewed Original ResearchEnd of treatmentSimilar clinical outcomesStandard chemotherapyClinical outcomesCapecitabine patientsQoL resultsTreatment recommendationsLess toxicityLeukemia Group B StudyRandomized phase III trialBetter overall QoLPatients 65 yearsStandard chemotherapy armOlder cancer patientsPhase III trialsWorse clinical outcomesSystemic side effectsBetter body imageQuality of lifeCapecitabine armChemotherapy armLess constipationWorse diarrheaCapecitabine treatmentMetastatic settingTopical Amitriptyline-Baclofen Cream for the Treatment of Provoked Vestibulodynia
Nyirjesy P, Lev-Sagie A, Mathew L, Culhane J. Topical Amitriptyline-Baclofen Cream for the Treatment of Provoked Vestibulodynia. Journal Of Lower Genital Tract Disease 2009, 13: 230-236. DOI: 10.1097/lgt.0b013e31819663ee.Peer-Reviewed Original ResearchTherapy warrants further investigationOverall sexual lifeSexual lifeDatabase of womenVisual analog scaleSystemic side effectsRetrospective study designWarrants further investigationSelf-administered questionnaireRefractory symptomsSexual desireOverall tolerabilityAnalog scaleProvoked vestibulodyniaEntry criteriaVulvovaginal disordersRetrospective evaluationIntercourse frequencySide effectsPatientsControl groupResponse rateStudy designSexual intercourseModerate improvement
2008
Endothelial-targeted Gene Transfer of Hypoxia-inducible Factor-1α Augments Ischemic Neovascularization Following Systemic Administration
Tal R, Shaish A, Rofe K, Feige E, Varda-Bloom N, Afek A, Barshack I, Bangio L, Hodish I, Greenberger S, Peled M, Breitbart E, Harats D. Endothelial-targeted Gene Transfer of Hypoxia-inducible Factor-1α Augments Ischemic Neovascularization Following Systemic Administration. Molecular Therapy 2008, 16: 1927-1936. PMID: 28189008, DOI: 10.1038/mt.2008.191.Peer-Reviewed Original ResearchTherapeutic efficacyProangiogenic gene therapyHIF-1aMurine preproendothelin-1 promoterTail vein administrationPreproendothelin-1 promoterSystemic side effectsLack of therapeutic efficacySystemic IV administrationHypoxia-inducible factor 1aRoute of administrationIncreased capillary densityMouse hindlimb ischemia modelHindlimb ischemia modelDeliver genesEnhanced blood perfusionGene therapyIntraarterial routeC57BL/6 miceClinical outcomesSystemic toxicityIschemic neovascularizationSide effectsBiodistribution studiesIschemic muscleEndothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration.
Tal R, Shaish A, Rofe K, Feige E, Varda-Bloom N, Afek A, Barshack I, Bangio L, Hodish I, Greenberger S, Peled M, Breitbart E, Harats D. Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Molecular Therapy 2008, 16: 1927-36. PMID: 18797451, DOI: 10.1038/mt.2008.191.Peer-Reviewed Original ResearchConceptsHypoxia-inducible factor-1alphaSystemic administrationTherapeutic efficacyProangiogenic gene therapyFactor-1alphaSystemic side effectsEnhanced blood perfusionRoute of administrationTail vein administrationHindlimb ischemia modelMouse hindlimb ischemia modelMurine preproendothelin-1 promoterClinical outcomesPreproendothelin-1 promoterC57BL/6 miceIschemic neovascularizationIntravenous routeIschemic muscleIntraarterial routeIschemia modelCapillary densityIschemic regionSide effectsSystemic toxicityTherapeutic angiogenesisClinically Tolerated Strategies for NMDA Receptor Antagonism
Vincent Chen H, Zhang D, Lipton S. Clinically Tolerated Strategies for NMDA Receptor Antagonism. The Receptors 2008, 327-361. DOI: 10.1007/978-1-59745-055-3_8.Peer-Reviewed Original ResearchExcessive NMDAR activityNMDAR activityClinical trialsGlutamate receptorsSide effectsNeurologic disordersNervous systemAcute hypoxic-ischemic brain injuryGeneralized inhibitionAlzheimer's diseaseSecond-generation memantine derivativesHypoxic-ischemic brain injuryPhase 3 clinical trialsExcessive NMDAR activationSevere neuropathic painExcitatory amino acidsGlutamate-mediated neurotoxicityGlutamate receptor subtypesChronic neurodegenerative diseasesSystemic side effectsMajor excitatory transmitterNormal functionNMDA receptor antagonismGreater neuroprotective propertiesCentral nervous system
2007
Effect of Inhaled Tacrolimus on Cellular and Humoral Rejection to Prevent Posttransplant Obliterative Airway Disease
Schrepfer S, Deuse T, Reichenspurner H, Hoffmann J, Haddad M, Fink J, Fischbein M, Robbins R, Pelletier M. Effect of Inhaled Tacrolimus on Cellular and Humoral Rejection to Prevent Posttransplant Obliterative Airway Disease. American Journal Of Transplantation 2007, 7: 1733-1742. PMID: 17532751, DOI: 10.1111/j.1600-6143.2007.01858.x.Peer-Reviewed Original ResearchConceptsObliterative airway diseaseTreatment groupsAirway diseaseSystemic side effectsCellular immune activationOrthotopic tracheal transplantationGraft infiltrationCellular rejectionCellular immunosuppressionHumoral rejectionAllograft rejectionElevated BUNImmune activationTacrolimusAerosol inhalationMononuclear infiltrationSide effectsPOD 8Tracheal transplantationAirway graftsPO animalsHistology of graftsGraftTreatmentPods
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply